0853 (0853) Fair Value & Analysis

Healthcare · Market cap HK$12.2B

0 0853 0853 · HK

PriceHK$6.17

Fair ValueHK$3.37

Upside-45.4%

Quality38/100

Evidence: Medium Range HK$2.51 – HK$4.24

Fair value as of: Jul 2, 2026

From 11 valuation models · updated today

Share price −18.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$5.91 – HK$16.16 · fair‑value band HK$2.51 – HK$4.24 · the HK$6.17 price screens above the HK$3.37 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0853 (0853) currently trades at HK$6.17, while our model-based Fair Value estimate is HK$3.37 — implying the stock looks roughly 45.4% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0853 generated revenue of HK$1.1B at a net margin of 4.4%. Revenue grew 18.1% year over year. It earns a return on equity of 2.9%. Net debt stands at HK$918M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B

Revenue growth (YoY) +18.1%

Net margin 4.4%

Return on equity 2.9%

Free cash flow −HK$77.7M FY2025

Operating margin -6.8%

More key figures

EPS (TTM) HK$-0.0300

EPS growth (YoY) +123%

Net debt HK$918M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0853 reported revenue of HK$996M in FY2025 versus HK$779M in FY2021, a compound +6.4%/yr. Reported net income was HK$48.6M in FY2025.

Revenue +6.4%/yr

FY21 HK$779M

FY22 HK$841M

FY23 HK$951M

FY24 HK$1.0B

FY25 HK$996M

Net income

FY21 −HK$276M

FY22 −HK$437M

FY23 −HK$478M

FY24 −HK$214M

FY25 HK$48.6M

Is 0853 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	1,600 MXN	1,228 MXN	-23%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$248.75	R$221.81	-11%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%
Siemens Healthineers AG SEMHF	$40.29	$47.96	+19%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0853 (0853) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.37 versus a price of HK$6.17 — about −45% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0853?

Our model-based fair value for 0853 is HK$3.37 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$6.17.

What is the quality score of 0853?

0853 has a Quality Score of 38/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0853 (0853)?

0853 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0853?

The net profit margin of 0853 is about 4.4%, meaning it keeps roughly 4.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.